|Mr. Sebastien Plouffe||CEO, Pres & Director||82.5k||N/A||1972|
|Mr. Patrick Joseph Meagher C.A., CPA, CA, CPA||CFO & Director||54k||N/A||1986|
|Dr. Simon Beaudoin||Chief Technical Science Officer||N/A||N/A||1984|
|Dr. Moutih Rafei Ph.D.||VP of R&D and Director||N/A||N/A||1983|
|Ms. Carrie Cesarone||Corp. Sec.||N/A||N/A||1965|
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Defence Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.